Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Work In Process (2019 - 2025)

Historic Work In Process for Ptc Therapeutics (PTCT) over the last 7 years, with Q3 2025 value amounting to $41.8 million.

  • Ptc Therapeutics' Work In Process rose 7114.16% to $41.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.8 million, marking a year-over-year increase of 7114.16%. This contributed to the annual value of $12.2 million for FY2024, which is 3209.94% down from last year.
  • Per Ptc Therapeutics' latest filing, its Work In Process stood at $41.8 million for Q3 2025, which was up 7114.16% from $24.4 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Work In Process high stood at $41.8 million for Q3 2025, and its period low was $7.0 million during Q2 2022.
  • Its 5-year average for Work In Process is $16.5 million, with a median of $14.1 million in 2022.
  • In the last 5 years, Ptc Therapeutics' Work In Process surged by 24787.84% in 2023 and then tumbled by 4108.58% in 2025.
  • Ptc Therapeutics' Work In Process (Quarter) stood at $7.7 million in 2021, then skyrocketed by 82.28% to $14.1 million in 2022, then rose by 27.83% to $18.0 million in 2023, then plummeted by 32.1% to $12.2 million in 2024, then soared by 242.4% to $41.8 million in 2025.
  • Its Work In Process stands at $41.8 million for Q3 2025, versus $24.4 million for Q2 2025 and $13.1 million for Q1 2025.